TAK — Takeda Pharmaceutical Co News Story

0.000.00%

Last trade - 00:00

HealthcareConservativeLarge CapNeutral

Market Cap
$41.22bn
Enterprise Value
$69.15bn
Revenue
¥4tn

All News

REG-Millennium Partners, L.P. Form 8.3 - Takeda Pharmaceutical Company Limited

Takeda Pharmaceutical CoAnnouncement

28/12/2018 15:15

Form 8.3 - Takeda Pharmaceutical Company Limited

FORM 8.3

PUBLIC OPENING POSITION DISCLOSURE/DEALING DISCLOSURE BY

A PERSON WITH INTERESTS IN RELEVANT SECURITIES REPRESENTING 1% OR MORE

Rule 8.3 of the Takeover Code (the “Code”)

1. KEY INFORMATION

(a) Full name of discloser:		Millennium International Management LP
(b) Owner or controller of interests and short positions disclosed, if different from 1(a): The naming of nominee or vehicle companies is insufficient. For a trust, the trustee(s), settlor and beneficiaries must be named.
(c) Name of offeror/offeree in relation to whose relevant securities this form relates: Use a separate form for each offeror/offeree		Takeda Pharmaceutical Company Limited
(d) If an exempt fund manager connected with an offeror/offeree, state this and specify identity of offeror/offeree:
(e) Date position held/dealing undertaken: For an opening position disclosure, state the latest practicable date prior to the disclosure		27^th December 2018
(f) In addition to the company in 1(c) above, is the discloser making disclosures in respect of any other party to the offer? If it is a cash offer or possible cash offer, state “N/A”		Yes, Shire plc

2. POSITIONS OF THE PERSON MAKING THE DISCLOSURE

If there are positions or rights to subscribe to disclose in more than one class of relevant securities of the offeror or offeree named in 1(c), copy table 2(a) or (b) (as appropriate) for each additional class of relevant security.

(a) Interests and short positions in the relevant securities of the offeror or offeree to which the disclosure relates following the dealing (if any)

Class of relevant security:	Ordinary (JP3463000004) - interest held via holding of ADS and ADS Option (US8740602052)
	Interests		Short positions
	Number	%	Number	%
(1) Relevant securities owned and/or controlled:	382,500	0.049%	11,489,884	1.465%
(2) Cash-settled derivatives:	1,179,294	0.150%	807,173	0.103%
(3) Stock-settled derivatives (including options) and agreements to purchase/sell:	250,000	0.032%	0	0.000%
TOTAL:	1,811,794	0.231%	12,297,057	1.568%

All interests and all short positions should be disclosed.

Details of any open stock-settled derivative positions (including traded options), or agreements to purchase or sell relevant securities, should be given on a Supplemental Form 8 (Open Positions).

(b) Rights to subscribe for new securities (including directors’ and other employee options)

Class of relevant security in relation to which subscription right exists:
Details, including nature of the rights concerned and relevant percentages:

3. DEALINGS (IF ANY) BY THE PERSON MAKING THE DISCLOSURE

Where there have been dealings in more than one class of relevant securities of the offeror or offeree named in 1(c), copy table 3(a), (b), (c) or (d) (as appropriate) for each additional class of relevant security dealt in.

The currency of all prices and other monetary amounts should be stated.

(a) Purchases and sales

Class of relevant security	Purchase/sale	Number of securities	Price per unit (USD)
US8740602052	Purchase	100	16.54
US8740602052	Purchase	100	16.59
US8740602052	Purchase	1,491	16.61
US8740602052	Purchase	200	16.62
US8740602052	Purchase	1,491	16.63
US8740602052	Purchase	1,080	16.64
US8740602052	Purchase	1,100	16.65
US8740602052	Purchase	1,300	16.66
US8740602052	Purchase	100	16.67
US8740602052	Purchase	300	16.68
US8740602052	Purchase	500	16.69
US8740602052	Purchase	82	16.71
US8740602052	Purchase	100	16.72
US8740602052	Purchase	300	16.73
US8740602052	Purchase	300	16.77
US8740602052	Purchase	100	16.78
US8740602052	Purchase	100	16.79
US8740602052	Purchase	5	16.80
US8740602052	Purchase	100	16.82
US8740602052	Purchase	1,172	16.85
US8740602052	Purchase	1,000	16.86
US8740602052	Purchase	300	16.87
US8740602052	Purchase	975	16.88
US8740602052	Purchase	104	16.94
US8740602052	Purchase	400	16.95
US8740602052	Sale	2,472	16.79
US8740602052	Sale	25,170	16.86
US8740602052	Sale	293	16.90
US8740602052	Sale	65	16.91
US8740602052	Purchase	100	16.56
US8740602052	Purchase	100	16.60
US8740602052	Purchase	600	16.61
US8740602052	Purchase	200	16.62
US8740602052	Purchase	4,000	16.63
US8740602052	Purchase	200	16.64
US8740602052	Purchase	300	16.65
US8740602052	Purchase	100	16.66
US8740602052	Purchase	4,200	16.67
US8740602052	Purchase	4,300	16.68
US8740602052	Purchase	272	16.69
US8740602052	Purchase	100	16.70
US8740602052	Purchase	264	16.71
US8740602052	Purchase	200	16.72
US8740602052	Purchase	100	16.73
US8740602052	Purchase	100	16.84
US8740602052	Purchase	100	16.85
US8740602052	Purchase	300	16.88
US8740602052	Purchase	100	16.89
US8740602052	Purchase	100	16.90
US8740602052	Purchase	10,000	16.92
US8740602052	Purchase	300	16.94
US8740602052	Purchase	352	16.95

Class of relevant security	Purchase/sale	Number of securities	Price per unit (JPY)
JP3463000004	Sale	100	3,748
JP3463000004	Sale	300	3,751
JP3463000004	Sale	100	3,752
JP3463000004	Sale	300	3,754
JP3463000004	Sale	200	3,757
JP3463000004	Sale	200	3,762
JP3463000004	Sale	100	3,764
JP3463000004	Sale	100	3,765
JP3463000004	Sale	200	3,767
JP3463000004	Sale	100	3,773
JP3463000004	Sale	100	3,774
JP3463000004	Sale	100	3,775
JP3463000004	Sale	200	3,777
JP3463000004	Sale	200	3,778
JP3463000004	Sale	200	3,781
JP3463000004	Sale	400	3,783
JP3463000004	Sale	200	3,787
JP3463000004	Sale	200	3,789
JP3463000004	Sale	200	3,790
JP3463000004	Sale	200	3,791
JP3463000004	Sale	6,800	3,792
JP3463000004	Sale	200	3,794
JP3463000004	Sale	300	3,799
JP3463000004	Sale	100	3,800
JP3463000004	Sale	200	3,801
JP3463000004	Sale	200	3,802
JP3463000004	Sale	100	3,803
JP3463000004	Sale	500	3,806
JP3463000004	Sale	5,000	3,807
JP3463000004	Sale	100	3,809
JP3463000004	Sale	100	3,810
JP3463000004	Sale	200	3,811
JP3463000004	Sale	300	3,813
JP3463000004	Sale	100	3,816
JP3463000004	Sale	200	3,817
JP3463000004	Sale	100	3,819
JP3463000004	Sale	200	3,820
JP3463000004	Sale	100	3,821
JP3463000004	Sale	200	3,824
JP3463000004	Sale	100	3,825
JP3463000004	Sale	200	3,827
JP3463000004	Sale	100	3,828
JP3463000004	Sale	100	3,829
JP3463000004	Sale	100	3,833
JP3463000004	Sale	200	3,834
JP3463000004	Sale	100	3,837
JP3463000004	Sale	100	3,839
JP3463000004	Sale	200	3,841
JP3463000004	Sale	300	3,845
JP3463000004	Sale	1,700	3,850
JP3463000004	Purchase	200	3,785
JP3463000004	Purchase	100	3,786
JP3463000004	Purchase	200	3,787
JP3463000004	Purchase	4,300	3,787
JP3463000004	Purchase	800	3,788
JP3463000004	Purchase	900	3,790
JP3463000004	Purchase	100	3,790
JP3463000004	Purchase	900	3,792
JP3463000004	Purchase	100	3,793
JP3463000004	Purchase	100	3,794
JP3463000004	Purchase	300	3,796
JP3463000004	Purchase	1,700	3,796
JP3463000004	Purchase	100	3,797
JP3463000004	Purchase	200	3,798
JP3463000004	Purchase	100	3,800
JP3463000004	Purchase	200	3,801
JP3463000004	Purchase	100	3,802
JP3463000004	Purchase	400	3,802
JP3463000004	Purchase	100	3,803
JP3463000004	Purchase	100	3,803
JP3463000004	Purchase	5,000	3,803
JP3463000004	Purchase	1,300	3,803
JP3463000004	Purchase	300	3,804
JP3463000004	Purchase	100	3,804
JP3463000004	Purchase	1,300	3,804
JP3463000004	Purchase	100	3,806
JP3463000004	Purchase	100	3,806
JP3463000004	Purchase	700	3,808
JP3463000004	Purchase	500	3,809
JP3463000004	Purchase	1,700	3,809
JP3463000004	Purchase	2,000	3,809
JP3463000004	Purchase	600	3,810
JP3463000004	Purchase	3,100	3,810
JP3463000004	Purchase	400	3,811
JP3463000004	Purchase	200	3,811
JP3463000004	Purchase	100	3,812
JP3463000004	Purchase	400	3,813
JP3463000004	Purchase	200	3,814
JP3463000004	Purchase	500	3,815
JP3463000004	Purchase	400	3,815
JP3463000004	Purchase	400	3,815
JP3463000004	Purchase	400	3,816
JP3463000004	Purchase	200	3,816
JP3463000004	Purchase	200	3,817
JP3463000004	Purchase	1,600	3,818
JP3463000004	Purchase	200	3,819
JP3463000004	Purchase	100	3,820
JP3463000004	Purchase	8,500	3,821
JP3463000004	Purchase	200	3,823
JP3463000004	Purchase	100	3,824
JP3463000004	Purchase	100	3,824
JP3463000004	Purchase	100	3,825
JP3463000004	Purchase	100	3,825
JP3463000004	Purchase	100	3,826
JP3463000004	Purchase	100	3,826
JP3463000004	Purchase	3,700	3,827
JP3463000004	Purchase	100	3,830
JP3463000004	Purchase	2,400	3,830
JP3463000004	Purchase	100	3,835
JP3463000004	Purchase	100	3,837
JP3463000004	Purchase	200	3,837
JP3463000004	Purchase	100	3,839
JP3463000004	Purchase	100	3,840
JP3463000004	Purchase	100	3,841
JP3463000004	Purchase	100	3,842
JP3463000004	Purchase	100	3,843
JP3463000004	Purchase	100	3,843
JP3463000004	Purchase	300	3,843
JP3463000004	Purchase	300	3,844
JP3463000004	Purchase	300	3,844
JP3463000004	Purchase	600	3,845
JP3463000004	Purchase	400	3,845
JP3463000004	Purchase	400	3,846
JP3463000004	Purchase	300	3,847
JP3463000004	Purchase	200	3,847
JP3463000004	Purchase	100	3,848
JP3463000004	Purchase	100	3,849
JP3463000004	Purchase	400	3,850
JP3463000004	Purchase	100	3,850
JP3463000004	Purchase	100	3,851
JP3463000004	Purchase	2,600	3,851
JP3463000004	Purchase	5,800	3,851
JP3463000004	Purchase	100	3,852
JP3463000004	Purchase	1,200	3,852
JP3463000004	Purchase	100	3,854
JP3463000004	Purchase	200	3,855
JP3463000004	Purchase	300	3,856
JP3463000004	Purchase	400	3,858
JP3463000004	Purchase	100	3,859
JP3463000004	Purchase	500	3,860
JP3463000004	Purchase	400	3,861
JP3463000004	Purchase	200	3,861
JP3463000004	Purchase	100	3,862
JP3463000004	Purchase	100	3,863
JP3463000004	Sale	100	3,756
JP3463000004	Sale	100	3,763
JP3463000004	Sale	100	3,775
JP3463000004	Sale	200	3,789
JP3463000004	Sale	100	3,790
JP3463000004	Sale	100	3,792
JP3463000004	Sale	100	3,802
JP3463000004	Sale	100	3,804
JP3463000004	Sale	100	3,806
JP3463000004	Sale	100	3,809
JP3463000004	Sale	100	3,810
JP3463000004	Sale	100	3,815
JP3463000004	Sale	100	3,816
JP3463000004	Sale	100	3,822
JP3463000004	Sale	100	3,826
JP3463000004	Sale	200	3,840
JP3463000004	Sale	100	3,849
JP3463000004	Sale	100	3,850
JP3463000004	Sale	200	3,861
JP3463000004	Sale	3,000	3,850
JP3463000004	Purchase	100	3,803
JP3463000004	Purchase	1,700	3,804
JP3463000004	Purchase	100	3,809
JP3463000004	Purchase	100	3,814
JP3463000004	Purchase	100	3,815
JP3463000004	Purchase	200	3,816
JP3463000004	Purchase	100	3,817
JP3463000004	Purchase	100	3,822
JP3463000004	Purchase	100	3,833
JP3463000004	Purchase	100	3,843
JP3463000004	Purchase	100	3,843
JP3463000004	Purchase	100	3,844
JP3463000004	Purchase	300	3,845
JP3463000004	Purchase	100	3,845
JP3463000004	Purchase	100	3,855

(b) Cash-settled derivative transactions

Class of relevant security	Product description e.g. CFD	Nature of dealing e.g. opening/closing a long/short position, increasing/reducing a long/short position	Number of reference securities	Price per unit (JPY)
JP3463000004	CFD	Reducing a long position	8,600	3,816.45
JP3463000004	CFD	Reducing a long position	22,000	3,808.42
JP3463000004	CFD	Reducing a long position	2,600	3,814.50

(c) Stock-settled derivative transactions (including options)

(i) Writing, selling, purchasing or varying

Class of relevant security

Product description e.g. call option

Writing, purchasing, selling, varying etc.

Number of securities to which option relates

Exercise price per unit

Type

e.g. American, European etc.

Expiry date

Option money paid/ received per unit

(ii) Exercise

Class of relevant security

Product description

e.g. call option

Exercising/ exercised against

Number of securities

Exercise price per unit

(d) Other dealings (including subscribing for new securities)

Class of relevant security

Nature of dealing

e.g. subscription, conversion

Details

Price per unit (if applicable)

4. OTHER INFORMATION

(a) Indemnity and other dealing arrangements

Details of any indemnity or option arrangement, or any agreement or understanding, formal or informal, relating to relevant securities which may be an inducement to deal or refrain from dealing entered into by the person making the disclosure and any party to the offer or any person acting in concert with a party to the offer:

Irrevocable commitments and letters of intent should not be included. If there are no such agreements, arrangements or understandings, state “none”

NONE

(b) Agreements, arrangements or understandings relating to options or derivatives

Details of any agreement, arrangement or understanding, formal or informal, between the person making the disclosure and any other person relating to:

(i) the voting rights of any relevant securities under any option; or

(ii) the voting rights or future acquisition or disposal of any relevant securities to which any derivative is referenced:

If there are no such agreements, arrangements or understandings, state “none”

NONE

(c) Attachments

Is a Supplemental Form 8 (Open Positions) attached?

YES

Date of disclosure:		28^th December 2018
Contact name:		Myriam Soper
Telephone number:		+44 203 650 8261

Public disclosures under Rule 8 of the Code must be made to a Regulatory Information Service and must also be emailed to the Takeover Panel at monitoring@disclosure.org.uk. The Panel’s Market Surveillance Unit is available for consultation in relation to the Code’s disclosure requirements on +44 (0)20 7638 0129.

The Code can be viewed on the Panel’s website at www.thetakeoverpanel.org.uk.

SUPPLEMENTAL FORM 8 (OPEN POSITIONS)

DETAILS OF OPEN STOCK-SETTLED DERIVATIVE (INCLUDING OPTION) POSITIONS, AGREEMENTS TO PURCHASE OR SELL ETC.

Note 5(i) on Rule 8 of the Takeover Code (the “Code”)

1. KEY INFORMATION

Full name of person making disclosure:		Millennium International Management LP
Name of offeror/offeree in relation to whose relevant securities the disclosure relates:		Takeda Pharmaceutical Company Limited

2. STOCK-SETTLED DERIVATIVES (INCLUDING OPTIONS)

Class of relevant security

Product description e.g. call option

Written or purchased

Number of securities to which option or derivative relates

Exercise price per unit

Type

e.g. American, European etc.

Expiry date

US8740602052

Call Option

Purchased

250,000

4,200 JPY

American

20190308

3. AGREEMENTS TO PURCHASE OR SELL ETC.

Full details should be given so that the nature of the interest or position can be fully understood:

It is not necessary to provide details on a Supplemental Form (Open Positions) with regard to cash-settled derivatives.

The currency of all prices and other monetary amounts should be stated.

The Panel’s Market Surveillance Unit is available for consultation in relation to the Code’s disclosure requirements on +44 (0)20 7638 0129.

The Code can be viewed on the Panel’s website at www.thetakeoverpanel.org.uk

View source version on businesswire.com: https://www.businesswire.com/news/home/20181228005145/en/

Millennium Partners, L.P.

TAK — Takeda Pharmaceutical Co News Story

REG-Millennium Partners, L.P. Form 8.3 - Takeda Pharmaceutical Company Limited

Recent news on Takeda Pharmaceutical Co

REG - Malin Corp PLC - Malin Announces 2021 Full Year Results

REG - Takeda Pharma.Co.Ltd Shire plc - Confirmation of post-offer intention statements

REG - Morgan Stanley&CoLLC Takeda Pharma.Co.Ltd - Form 8.5 (EPT/RI) - Replacement of Takeda

REG - Takeda Pharma.Co.Ltd Shire plc - Statement re Applicable Exchange Rate

REG - Morgan Stanley Takeda Pharma.Co.Ltd - Form 8.5 (EPT/NON-RI) - Replacement of Takeda